Related Experiment Videos
Serum-Zn-levels in prostatic cancer.
A Feustel1, R Wennrich, B Schmidt
1Department of Urology, Markkleeberg Hospital, Leipzig, German Democratic Republic.
Urological Research
|January 1, 1989
Summary
Serum zinc levels are lower in men with advanced prostate cancer and those undergoing hormone therapy. This finding highlights the potential role of zinc in prostate cancer progression and treatment.
Area of Science:
- Biochemistry
- Oncology
- Urology
Background:
- Prostate cancer is a significant health concern in men.
- Serum zinc levels may be altered in various disease states.
- The role of zinc in prostate carcinoma is not fully understood.
Purpose of the Study:
- To investigate serum zinc concentrations in patients with prostate cancer.
- To compare zinc levels between different stages of prostate cancer and healthy controls.
- To assess the impact of metastasis and hormone therapy on serum zinc.
Main Methods:
- Serum samples were collected from patients with prostate carcinoma and healthy men.
- Zinc concentration was determined using flame atomic absorption spectrometry (FAAS).
- Statistical analysis was performed to compare zinc levels across groups.
Main Results:
- No significant difference in serum zinc was observed between early-stage prostate cancer patients and controls.
- Significantly decreased serum zinc levels were found in patients with metastatic prostate cancer.
- Men without metastases showed reduced serum zinc after orchiectomy and hormone therapy.
Conclusions:
- Serum zinc levels decrease with advanced prostate cancer and metastasis.
- Hormone therapy and orchiectomy may lead to reduced zinc concentrations.
- Further research is warranted to explore the clinical significance of these findings.